上海联影医疗科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688271 证券简称：联影医疗 公告编号：2025-029 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/24 | 2025/7/25 | 2025/7/25 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经上海联影医疗科技股份有限公司（以下简称"联影医疗" 或"公司"）2025 年 6 月 30 日的2024年年度股东会审议通过。 二、 分配方案 1. 发放年度：2024年年度 是否涉及差异化分红送转：是 每股分配比例 每股现金红利0.08元（含税） 相关日期 案》，公司拟以实施权益分派股权登记日登记的总股本扣减公司回购专用证券账户 中的股份为基数，向全体股东每 10 股派发现金红利 0.80 元（含税），不进行资本 公积转增股本，不送红股。根据《关于公司 2024 年年度利润分配预案的议案》， 在实施权益 ...

Core Viewpoint - The 2025 Global MedTech Top 100 (GMT100) list highlights the dominance of major players in the medical technology industry while showcasing the rise of Chinese and Asia-Pacific companies in the global market [3][4][5]. Global Overview - The top 10 companies continue to dominate the market, with Medtronic leading at a revenue of 239.45 billion RMB for 2024. The total revenue of the top 10 exceeds 1.6 trillion RMB, accounting for over 60% of the total revenue of the list [5][14]. - The list reflects a "pyramid" structure in the medical technology industry, where smaller companies focus on niche markets but show significant innovation and growth potential [10][11]. Regional Distribution - North American companies hold a significant share of the list, with the top 10 generating over 16 trillion RMB in revenue. Asian companies, particularly from China, are increasingly making their presence felt [11][14]. - Chinese companies have shown remarkable performance, with 12 firms making it to the top 100, collectively generating over 200 billion RMB in revenue for 2024, marking a further increase from the previous year [4][14]. Industry Concentration and Future Outlook - The medical technology industry exhibits a "Matthew Effect," where the top 10 companies control over 60% of the market share, while emerging companies challenge traditional players with innovative technologies [13][14]. - The future of the industry is expected to witness significant technological changes and market reshuffling, with the GMT100 serving as a record of these developments [13][14].

金十数据7月17日讯，据湖北发布，7月17日，湖北省委书记、省人大常委会主任王忠林在武汉市调研民 营企业发展并主持召开座谈会。在座谈会上，亿纬锂能、联影集团、美的集团、骆驼集团、禾元生物、 帝尔激光、九州通、高德红外、楚能新能源、宜昌邦普、菲利华石英玻璃、抖音集团、京东集团、两点 十分文化传播等民营企业相关负责人代表先后发言，介绍企业生产经营情况，就做好下半年经济工作和 促进民营经济健康发展提出意见建议。王忠林强调，要全力帮助企业降本增效，聚焦企业关注的关键要 素，打好降本增效"组合拳"。要全力解决拖欠企业账款问题，健全清偿机制，实行销号管理，加大惩戒 力度。 湖北省委书记王忠林在武汉调研民营企业发展并召开座谈会 ...

Core Viewpoint - The A-share market experienced an overall increase on July 17, with significant net inflows of capital, indicating a positive sentiment among investors [1][2]. Group 1: Market Performance - The Shanghai Composite Index closed at 3516.83 points, up 0.37%, while the Shenzhen Component Index rose by 1.43% to 10873.62 points, and the ChiNext Index increased by 1.75% to 2269.33 points [1]. - The total trading volume of both markets reached 15393.69 billion yuan, an increase of 973.31 billion yuan compared to the previous trading day [1]. Group 2: Capital Flow - The net inflow of main funds in the two markets was approximately 69.86 billion yuan, with an opening net outflow of 16.82 billion yuan and a tail-end net inflow of 13.64 billion yuan [2][3]. - The CSI 300 index saw a net inflow of 50.83 billion yuan, while the ChiNext index had a net inflow of 19.64 billion yuan [2][4]. Group 3: Sector Performance - The electronics sector led with a net inflow of 186.98 billion yuan, followed by defense and military with 77.12 billion yuan, and the computer sector with 55.97 billion yuan [5]. - Conversely, the public utilities sector experienced a net outflow of 51.77 billion yuan, with transportation and banking sectors also seeing outflows of 22.70 billion yuan and 16.86 billion yuan, respectively [5]. Group 4: Institutional Activity - The top stocks with significant institutional net purchases included Meidi Xi with a 19.00% increase and a net buy of 140.19 million yuan, and Mankun Technology with a 20.01% increase and a net buy of 86.33 million yuan [8]. - Notable stocks with institutional interest also included Nanjing Jujian and Shouyao Holdings, both showing substantial price increases and net purchases [8]. Group 5: Analyst Ratings - China Shenhua received a "Buy" rating from Guotai Junan with a target price of 44.79 yuan, indicating a potential upside of 20.63% from its latest closing price [10]. - Jiangfeng Electronics was rated "Buy" by Guotai Junan with a target price of 83.27 yuan, suggesting a potential increase of 20.33% [10].

Core Viewpoint - The article highlights the significant growth in China's high-tech product exports, particularly in the instrumentation sector, which has shown a robust performance in the international market due to increased R&D investment and favorable conditions from initiatives like the Belt and Road [3][4]. Group 1: Export Growth - In the first half of 2025, China's instrumentation exports grew by 14.7%, continuing a trend of double-digit growth for nine consecutive months [2][3]. - The total export value of scientific instruments in 2024 is projected to be $5.57 billion, reflecting a year-on-year increase of 2.71% [3]. Group 2: Industry Development - The growth in exports is attributed to the continuous enhancement of product technology and quality within China's instrumentation industry, leading to greater international recognition [3]. - Notable domestic companies such as Guoyi Quantum, Junzheng Technology, BGI, United Imaging, and Prism Tech have successfully penetrated emerging overseas markets with competitive pricing and high-quality products [3]. Group 3: Economic Context - The Deputy Director of the General Administration of Customs, Wang Lingjun, emphasized that despite a complex global environment, China's foreign trade has shown resilience, maintaining growth in both scale and quality [3].

Group 1 - The core viewpoint of the articles emphasizes that the innovative drug sector in China is experiencing a transformation driven by international recognition, policy support, and market dynamics, leading to a potential revaluation cycle [1][5][9] - The total value of license-out transactions for Chinese innovative drugs exceeded $50 billion in 2023, with multiple drugs receiving FDA approval, indicating growing global market acceptance [1][5] - The Hong Kong stock market has become a preferred listing venue for Chinese innovative drug companies due to its international financing environment and flexible listing regulations, hosting numerous leading firms in cutting-edge fields such as oncology and gene therapy [1][5] Group 2 - The newly launched Hong Kong Stock Connect Innovative Drug ETF by Harvest Fund aims to provide investors with a one-click solution to invest in core assets of innovative drugs, tracking the CSI Hong Kong Stock Connect Innovative Drug Index [2][9] - The CSI Hong Kong Stock Connect Innovative Drug Index includes 50 companies involved in innovative drug research and development, with the top ten companies accounting for over 60% of the index's weight, showcasing significant representativeness [2][3] - As of July 15, 2025, the index has shown impressive performance, with a one-year increase of 109.13% and a year-to-date increase of 66.23%, outperforming similar indices and the broader market [4][5] Group 3 - The A-share Sci-Tech Innovation Board complements the Hong Kong market by attracting innovative drug companies with independent intellectual property, providing a financing channel for high-growth biotech firms [6][9] - The newly established Sci-Tech Medicine ETF by Harvest Fund tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index, covering various segments including innovative drugs and vaccines [6][9] - The combination of the Hong Kong and A-share markets creates a comprehensive investment strategy for Chinese innovative drugs, allowing investors to capture opportunities across the entire industry chain [9][10] Group 4 - The dual-market strategy of investing in both Hong Kong and A-share markets allows for a diversified approach, with the Hong Kong ETF focusing on mature innovative drug companies and the A-share ETF targeting early-stage firms with high growth potential [10][11] - This strategy aims to mitigate risks associated with market volatility while maximizing long-term investment value in the innovative drug sector [10][11] - Harvest Fund has developed a comprehensive ETF product line in the biopharmaceutical sector, including various thematic products to capture key industry opportunities [11]

Investment Rating - The report assigns a "Buy-A" investment rating to the company with a 6-month target price of 161.52 CNY, representing a dynamic price-to-earnings ratio of 60 times for 2025 [4][9]. Core Viewpoints - The company is positioned as a leading domestic player in medical imaging, with a strong focus on innovation and technology, comparable to top international manufacturers [1][14]. - The medical imaging industry is experiencing sustained growth, with China's market expected to grow at a compound annual growth rate (CAGR) of around 10% until 2030, significantly outpacing global growth [2][3]. - The company is witnessing a notable increase in both domestic and international market shares, with a CAGR of 93% in overseas revenue from 2018 to 2024 [3][9]. Summary by Sections Company Overview - The company has established itself as a leader in the domestic medical imaging sector since its inception in 2011, with a focus on high-quality product offerings and a robust R&D capability [14][16]. - The product line includes high-end medical imaging diagnostic products and radiation therapy products, aligning closely with offerings from international competitors like GE Healthcare and Siemens [1][21]. Core Growth Logic 1: Industry Growth - The global medical imaging equipment market surpassed 43 billion USD in 2020 and is projected to reach 63 billion USD by 2030, with a CAGR of nearly 4% [2]. - China's medical imaging market is expected to capture nearly 20% of the global market share by 2030, driven by high-end product demand and expanding market needs [2]. Core Growth Logic 2: Market Share Increase - The company has been rapidly increasing its market share domestically, with significant room for growth as current market shares for various product categories hover around 20% [3]. - The company's international strategy has led to a substantial increase in overseas revenue, which now accounts for approximately 20% of total revenue [3]. Marginal Catalysts - The medical equipment industry is experiencing a recovery in procurement and bidding processes, with a notable increase in tender amounts observed in early 2025 [4][8]. - The anticipated recovery in the industry is attributed to several factors, including a reasonable base for 2024, the revival of routine procurement, and accelerated construction of medical community systems [8]. Financial Forecast and Valuation - The company is expected to achieve revenue growth rates of 24.1%, 21.5%, and 20.2% for the years 2025 to 2027, with net profit growth rates of 75.8%, 19.8%, and 23.6% respectively [9][10].

Investment Rating - Industry investment rating: Stronger than the market (maintained) [1][23] Core Viewpoints - The demand for medical equipment bidding continues to be strong, with a significant recovery in procurement activities expected to improve company financial performance [3][5] - The overall market size for medical device bidding in China exceeded 80 billion yuan in the first half of 2025, showing a year-on-year growth of over 60% [3][11] - Major provinces driving the procurement include Liaoning, Hainan, Ningxia, Fujian, and Shanxi, with imaging equipment being the core focus of upgrades [3][5] Summary by Sections Market Trends - The procurement scale for medical devices has remained high since 2025, with June procurement figures showing significant year-on-year increases across various categories, such as ultrasound (1.391 billion yuan, +49%), CT (1.938 billion yuan, +59%), and MRI (1.531 billion yuan, +64%) [4][12][15] - The bidding recovery is evident, with monthly procurement figures for 2025 showing consistent growth, despite a slight slowdown in June [3][11] Company Performance - Leading companies are expected to benefit significantly from the recovery in equipment bidding, with firms like Mindray Medical projecting a noticeable recovery in overall performance starting from Q3 2025 [3][5][21] - In June 2025, the bidding amounts for major domestic companies were as follows: Mindray (623 million yuan, +15%), United Imaging (769 million yuan, +35%), and Kaili Medical (102 million yuan, +73%) [4][18] Investment Recommendations - The report suggests focusing on domestic leading enterprises that are enhancing their high-end and intelligent medical equipment layouts, such as Mindray Medical, United Imaging, Kaili Medical, and Aohua Endoscopy [5][21] - The continuous support for equipment updates from government policies is expected to positively impact the industry, with a projected increase in procurement activities [21]

Core Insights - The article highlights a positive market reaction to the National Healthcare Security Administration's initiation of the 11th batch of drug procurement, which favors innovative drug companies by exempting them from the procurement process for mature "old drugs" [1][2] Group 1: Market Performance - As of July 17, the Sci-Tech Innovation Biopharmaceutical ETF (588250.SH) rose by 1.47%, with its associated index, Sci-Tech Biopharmaceutical (000683.SH), increasing by 1.51% [1] - Key constituent stocks such as Zai Lab (5.00%), BeiGene (3.73%), and others showed significant gains, indicating strong investor interest in innovative drug firms [1] Group 2: Policy Impact - The new procurement policy is interpreted as a favorable development for innovative drug companies, leading to a positive market sentiment towards the sector [1] - The exemption of innovative drugs from the procurement process is expected to alleviate policy risks for companies in the innovation drug space [1] Group 3: Research Insights - Research from Shenwan Hongyuan indicates that AI technology is increasingly penetrating the pharmaceutical industry, enhancing drug molecule development success rates by 9%-18% and reducing development cycles by over 50% [1] - Shanxi Securities notes rapid sales growth of PDE3/4 inhibitors in COPD maintenance treatment, with companies advancing clinical trials for other indications, reflecting a dual drive of technological iteration and clinical demand in the biopharmaceutical sector [1]

Group 1: Economic Overview - The GDP growth rate for the first half of the year is 5.3%, driven by structural optimization in industries, with high-tech manufacturing value added increasing by 9.5% and equipment manufacturing by 10.2% [1] - Domestic demand is contributing more significantly to economic growth, with final consumption expenditure's contribution rising by 0.6 percentage points to 52.3% in Q2 [1] - Infrastructure investment from January to June increased by 4.6% year-on-year, while manufacturing investment rose by 7.5%, indicating effective fiscal policy support [1] Group 2: Chemical Industry Insights - Dow's closure of its UK organic silicon plant is expected to reduce overseas polysiloxane capacity from 106 million tons in 2024 to 91.5 million tons by 2026 [3][34] - The closure of Dow's UK plant, which accounts for 30% of Europe's organic silicon capacity, is likely to enhance China's export share to Europe, with an estimated 8.7 million tons of DMC production potentially representing 88% of China's exports to Europe in 2024 [3][35] - China's organic silicon demand is projected to grow at a CAGR of 15.5% from 2021 to 2024, with prices expected to rise as supply-demand dynamics improve [34] Group 3: Construction and Infrastructure - Cement demand is stabilizing, with production in the first half of 2025 at 815 million tons, down 4.3% year-on-year, while prices have decreased by 43 yuan per ton compared to the previous year [4] - The issuance of long-term special government bonds is anticipated to support infrastructure investment, which is expected to remain high in the second half of the year [6] Group 4: Medical Device Market - The total bid amount for medical devices in June 2025 reached 12.618 billion yuan, a 30% year-on-year increase, indicating a recovery in the bidding market [18][36] - Domestic brands like Mindray and United Imaging are seeing significant growth in bid amounts, with Mindray's total for June reaching 623 million yuan, up 15% year-on-year [18][36] Group 5: E-commerce and AI Applications - The company reported a 20% increase in net profit for the first half of 2025, driven by a robust platform growth and the introduction of AI applications for order acquisition [19][22] - The e-commerce segment has become a new growth engine, with transaction volumes increasing significantly, and the company is also entering the robotics sector through strategic partnerships [22][25] Group 6: Investment Recommendations - Recommended stocks include Xin'an Chemical, with a focus on companies benefiting from the closure of Dow's UK plant and the expected increase in China's export share [3][35] - The report suggests continued investment in high-growth sectors such as urban renewal, coal chemical, nuclear power, and steel structures, while also considering undervalued state-owned enterprises [6]